Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Chang, Ceila (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S341000, C514S342000, C514S343000, C546S268700, C546S269400, C546S272700, C546S280400, C546S283400
Reexamination Certificate
active
06906089
ABSTRACT:
Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2and R3are various substituent groups; andone of X1and X2is N or CR″, and the other is NR″ or CHR″ wherein R″ is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1and X2is N or CR″ then the other may be S or O;and their use as pharmaceuticals.
REFERENCES:
patent: 5955480 (1999-09-01), Chang
patent: 1 381 031 (1975-01-01), None
patent: A11 180 958 (1999-07-01), None
patent: WO9314081 (1993-07-01), None
patent: WO9821957 (1998-05-01), None
patent: WO0061576 (1999-10-01), None
Inman, Gareth J. et al, “SB-431542 is a Potent and Specific Inhibitor of TGF-b Superfamily Type I ALK Receptors ALK4, ALK5, & ALK7,” Molecular Pharmacology (2002), vol. 62 (1), pp. 65-74.
Gaster Laramie Mary
Harling John David
Chang Ceila
Coppins Janet L.
Furman Theodore R.
SmithKline Beecham Corporation
Stein-Fernandez Nora
LandOfFree
Triarylimidazole derivatives as cytokine inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triarylimidazole derivatives as cytokine inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triarylimidazole derivatives as cytokine inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491411